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Introduction
Donation of hematopoietic stem cells (HSC) in the form
of bone marrow (BM) or peripheral blood stem cells
(PBSC) is a commonly performed procedure, with more
than 40,000 donations from both volunteer unrelated
donors (URD) and related donors (RD) each year.1,2 Over
the past decade, donor registries such as the National
Marrow Donor Program (NMDP) have published detailed
data describing the URD experience, identifying individu-
als at increased risk for pain and collection-related symp-
toms, slower recovery, and severe adverse events.3-7 Data
describing the RD experience, however, are limited, with
only one large recent study.8 This may be because URD
are handled by registries that have a mandate to collect
and report safety data, whereas RD are cared for by local
transplant centers, whose primary focus is care for the
recipient and, in most countries, RD safety data are not
systematically collected. Inadequate data regarding RD is
a cause for concern for many reasons. While URD reg-
istries have rigorous standards for donor approval, sup-
ported by internal quality initiatives and efforts at interna-
tional standardization,9 there are no generally accepted
guidelines about deferral of a RD.
With these concerns in mind, North American
Investigators teamed with the National Marrow Donor
Program (NMDP) and the Center for International Blood
and Marrow Transplant Research (CIBMTR) to conduct a
prospective observational trial of RD who donated at 53
transplant centers in the United States between January
2010 and July 2014. This report describes our primary end
point comparing pain, toxicities and recovery of RD with
URD collected concurrently at 78 BM and 87 PBSC NMDP
collection centers. 
Methods
Prior to donation, RD underwent a medical evaluation including
a detailed history, physical examination, blood tests, and addition-
al work up as necessary according to center standards. RD
approved for donation were approached for consent for this
Institutional Review Board (IRB)-approved study. 
Unrelated donors provided written informed consent for partic-
ipation as required by the NMDP IRB. URD were evaluated for
medical suitability and comorbidities that would require further
evaluation or qualify for deferral for BM or PBSC donation as spec-
ified by NMDP standards.10,11
Data collection
A pre-donation form including history of pre-existing medical
conditions (comorbidities) was completed. Detailed collection-
related symptoms and pain were collected at five time points: pre-
donation, peri-donation [day +5 from start of granulocyte-colony
stimulating factor (G-CSF) for PBSCs and 1-2 days after BM collec-
tion], and 1, 6 and 12 months post donation. Toxicity was defined
by Common Toxicity Criteria measures for symptoms commonly
noted during PBSC and BM collection (fever, fatigue, skin rash,
local reactions to an injection, nausea, vomiting, anorexia, insom-
nia, dizziness, and syncope) and is called the Modified Toxicity
Criteria (MTC). This approach was validated by the NMDP and
has been published previously.4,5,12,13 Pain was graded from 0-4 as
none, mild, moderate, severe, or disabling. Pain and toxicity meas-
ures were assessed by the transplant center at pre- and peri-dona-
tion time points; the CIBMTR Survey Research Group was
responsible for follow-up assessments.
A product-specific collection form detailed information on the
collection procedure. A subset of donors underwent assessment of
long-term psychological recovery by established Health Related
Quality of Life instruments (reported previously14-16).  
Unlike unrelated donor registries, transplant centers lack uniform approaches to related donorassessment and deferral. To test whether related donors are at increased risk for donation-relatedtoxicities, we conducted a prospective observational trial of 11,942 related and unrelated donors
aged 18-60 years. Bone marrow (BM) was collected at 37 transplant and 78 National Marrow Donor
Program centers, and peripheral blood stem cells (PBSC) were collected at 42 transplant and 87 unrelated
donor centers in North America.  Possible presence of medical comorbidities was verified prior to dona-
tion, and standardized pain and toxicity measures were assessed pre-donation, peri-donation, and one
year following. Multivariate analyses showed similar experiences for BM collection in related and unre-
lated donors; however, related stem cell donors had increased risk of moderate [odds ratios (ORs)  1.42;
P<0.001] and severe (OR 8.91; P<0.001) pain and toxicities (OR 1.84; P<0.001) with collection. Related
stem cell donors were at increased risk of persistent toxicities (OR 1.56; P=0.021) and non-recovery from
pain (OR 1.42; P=0.001) at one year. Related donors with more significant comorbidities were at espe-
cially high risk for grade 2-4 pain (OR 3.43; P<0.001) and non-recovery from toxicities (OR 3.71; P<0.001)
at one  year.  Related donors with more significant comorbidities were at especially high risk for grade
2-4 pain (OR 3.43; P<0.001) and non-recovery from toxicities (OR 3.71; P<0.001) at one year.  Related
donors reporting grade ≥2 pain had significant decreases in Health-Related Quality of Life (HR-QoL)
scores at one month and one year post donation (P=0.004). In conclusion, related PBSC donors with
comorbidities are at increased risk for pain, toxicity, and non-recovery at one year after donation. Risk
profiles described in this study should be used for donor education, planning studies to improve the relat-
ed donor experience, and decisions regarding donor deferral. Registered at clinicaltrials.gov identifier:
00948636.
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Table 1. Demographics and collection characteristics of first-time bone marrow (BM) donors and first time peripheral blood stem cell (PBSC)
donors.
                                                                                                    First-time BM donors                                             First-time PBSC donors
                                                                                  RD                           URD                                           RD                          URD                      
Variable                                                                    N (%)                        N (%)                   Pa                 N (%)                        N (%)                    Pa
Number of donors                                                                 126                                 2553                                                    956                                8307                            
Number of centers                                                                 37                                    78                                                       42                                   87                              
Age at donation (years)                                                                                                                            <0.001                                                                                      <0.001
18 to 29                                                                                54 (43)                        1231 (48)                                           102 (11)                      4011 (48)                       
30 to 39                                                                                22 (17)                         702 (27)                                            135 (14)                      2091 (25)                       
40 to 49                                                                                21 (17)                         455 (18)                                            254 (27)                      1520 (18)                       
50 to 60                                                                                29 (23)                         165 (06)                                            465 (49)                       685 (08)                        
Median (range)                                                              33 (18-61)                     30 (19-60)                 0.070              49 (18-61)                    30 (18-61)                <0.001
Gender                                                                                                                                                           0.078                                                                                        <0.001
Male                                                                                     67 (53)                        1558 (61)                                           537 (56)                      5341 (64)                       
Female                                                                                59 (47)                         995 (39)                                            419 (44)                      2966 (36)                       
Weight (kg)                                                                                                                                                                                                                                                           
N Eval                                                                                      126                                 2553                                                    952                                8307                            
Median (range)                                                             83 (50-150)                   81 (40-154)                0.330             86 (43-198)                  82 (37-176)               <0.001
BMI (kg/m2)                                                                                                                                                  0.069                                                                                        <0.001
Underweight, <18.5                                                               0                                14 (01)                                              3 (<1)                          66 (01)                         
Normal, 18.5-24.9                                                              40 (33)                         867 (34)                                            209 (23)                      2884 (35)                       
Overweight, 25-29.9                                                          34 (28)                         938 (37)                                            325 (36)                      3064 (37)                       
Obese, 30+                                                                        47 (39)                         734 (29)                                            368 (41)                      2288 (28)                       
Unknown                                                                            5 (N/A)                          0 (N/A)                                             51 (N/A)                        5 (N/A)                         
Race                                                                                                                                                                0.003                                                                                        <0.001
Caucasian                                                                           89 (71)                        1637 (64)                                           788 (82)                      6132 (74)                       
Hispanic                                                                              15 (12)                         332 (13)                                             63 (07)                        698 (08)                        
African / African American                                              15 (12)                         188 (07)                                             58 (06)                        314 (04)                        
Asian / Pacific Islander                                                     4 (03)                          146 (06)                                             29 (03)                        444 (05)                        
Native American                                                                 3 (02)                           21 (01)                                               6 (01)                           62 (01)                         
Multiple races / other                                                           0                               208 (08)                                              7 (01)                          592 (07)                        
Unknown / declined                                                               0                                21 (01)                                               5 (01)                           65 (01)                         
Comorbidity groupb                                                                                                                                                                                                                                             
Comorbidities absent                                                      64 (51)                                                                                     403 (42)                                                               
Comorbidities present, acceptable                             22 (17)                                                                                     171 (18)                                                               
Comorbidities present, indeterminate                       29 (23)                                                                                     297 (31)                                                               
Comorbidities present, defer                                       11 (09)                                                                                      85 (09)                                                                
Unknown                                                                            0 (N/A)                                                                                     0 (N/A)                                                                
Year of donation                                                                                                                                           0.001                                                                                        <0.001
2010                                                                                      21 (17)                         496 (19)                                            113 (12)                      1604 (19)                       
2011                                                                                      38 (30)                         622 (24)                                            301 (31)                      1977 (24)                       
2012                                                                                      51 (40)                         757 (30)                                            375 (39)                      2370 (29)                       
2013                                                                                      16 (13)                         678 (27)                                            167 (17)                      2356 (28)                       
PBSC collection-related                                                                                                                                                                         
Number of days of collection                                                                                                                                                                                                                     <0.001
1                                                                                                                                                                                              646 (68)                      7478 (90)                       
2                                                                                                                                                                                              283 (30)                       829 (10)                        
3                                                                                                                                                                                               16 (02)                               0                               
4                                                                                                                                                                                               10 (01)                               0                               
5                                                                                                                                                                                                1 (<1)                                0                               
Average daily G-CSF dose ( g)                                                                                                                                                                                                                      
N Eval                                                                                                                                                                                         918                                8183                            
Median (range)                                                                                                                                                             948 (300-2040)            900 (420-1260)            <0.001
continued on the next page 
End points
Pain was assessed for the following sites: back, bones, head,
hip, intravenous injection (IV) site, joints, limbs, muscles, neck,
throat, or other. Severity of pain was defined as the maximum
grade among these pain sites. Body symptoms were assessed
using the MTC outlined above and the peak toxicity level across
symptoms was analyzed. Recovery to pre-donation levels by one
year was defined as a pain or symptom score less than or equal to
the score at pre-donation.  
Pre-donation comorbidity ascertainment included: assessment
of bleeding, gastrointestinal, genitourinary, hematologic, hepatic,
pulmonary, cardiovascular, psychiatric, central nervous system
(CNS), endocrine, autoimmune disorders, or other significant
coexisting diseases (Online Supplementary Table S1). We divided
comorbidities into three categories: 1) comorbidities that would
not result in deferral from URD donation according to NMDP
standards;10,11 2) comorbidities that would have resulted in defer-
ral; and 3) comorbidities that could possibly have led to a deferral,
but more detailed donor clinical data would be needed to make
that judgment. 
Statistical analysis 
Analyses were conducted separately for BM and PB donations.
Pre-donation baseline variables were compared between RD and
URD groups using the Pearson c2 test for categorical variables and
the Kruskal-Wallis test for continuous variables. 
c2 tests or Fisher’s Exact tests as appropriate were used to com-
pare the incidences of skeletal pain and MTC symptoms as well
as recovery to pre-donation levels between RD and URD groups.
Multivariate analyses using logistic regression models were con-
ducted to compare the RD and URD groups accounting for differ-
ences in donor characteristics. The following donor characteristics
were examined for inclusion in the multivariate model: donor
type, race, gender, age, Body Mass Index (BMI), collection year,
comorbidity status among related donors, pre-donation counts
[white blood cell (WBC) count, platelets, neutrophils, mononu-
clear cells, hemoglobin], and pre-donation symptoms (skeletal
pain or maximum MTC grade). Additional PB donation-specific
variables considered were: placement of a central venous line,
total blood volume, absolute CD34+ cells and WBC pre-collection,
and daily GCSF dose (absolute and per kg).
The effects were estimated via odds ratios (OR). In all multivari-
ate models, donor type was forced into the model and stepwise
model selection was used to determine additional donor charac-
teristics to be included. Interactions between donor type and each
donor characteristic were tested for in all multivariate models.
Results
Demographics
Table 1 details RD and URD donating BM or PBSC. RD
tended to be older than URD, with 23% versus 6% of BM
donors and 49% versus 8% of PBSC donors collected  aged
between  50-60 years. Although males donated more
often in both RD and URD groups, a higher percentage of
females donated in the RD group. There was a trend
toward higher BMI in RD versus URD giving BM (BMI
30+, 39% versus 29%; P=0.07), and a significant difference
in obesity in RD versus URD giving PBSC with 41% versus
28% (BMI 30+; P<0.001). 
There are several notable differences between RD and
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Average daily G-CSF dose per donor weight ( g/kg/day)                                                                                                                                                                        
N Eval                                                                                                                                                                                         914                                8183                            
Median (range)                                                                                                                                                             10.3 (4.7-22.1)             10.6 (5.5-18.7)            <0.001
Absolute CD34+ at pre-collection                                                                                                                                                                                                                    
N Eval                                                                                                                                                                                         539                                8283                            
Median (range)                                                                                                                                                             87.0 (7.1-1342)            80.0 (0.3-2123)            <0.001
Total blood volume processed                                                                                                                                                                                                                  <0.001
Small, <12 L                                                                                                                                                                          54 (06)                        233 (03)                        
Standard, 12-18 L                                                                                                                                                                325 (34)                      1882 (23)                       
Large, ≥ 18 L                                                                                                                                                                        576 (60)                      6182 (75)                       
Unknown                                                                                                                                                                                1 (N/A)                        10 (N/A)                        
Median (range)                                                                                                                                                            20.0 (0.3-112.6)            21.2 (0.7-45.4)              0.040
Central line placement-Male                                                                                                                                                                                                                     <0.001
No                                                                                                                                                                                           470 (88)                      5219 (98)                       
Yes                                                                                                                                                                                           67 (12)                         121 ( 2)                        
Unknown                                                                                                                                                                                0 (N/A)                         1 (N/A)                         
Central line placement-Female                                                                                                                                                                                                                 <0.001
No                                                                                                                                                                                           259 (62)                      2460 (83)                       
Yes                                                                                                                                                                                          160 (38)                       506 (17)                        
Central line site-All donors                                                                                                                                                                                                                              
Femoral                                                                                                                                                                                   8 ( 4)                          209 (33)                  <0.001
Internal jugular                                                                                                                                                                   208 (92)                       389 (62)                        
Subclavian                                                                                                                                                                              11 ( 5)                          26 ( 4)                         
Other site                                                                                                                                                                                    0                                3 (<1)                         
RD: related donor; URD: unrelated donor; N: number; N Eval: number evaluated; BMI: Body Mass Index; G-CSF: granulocyte-colony stimulating factor. aPearson c2 test was used
for comparing discrete variables; the Kruskal-Wallis test was used for comparing continuous variables. bApplicable to RD only.
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URD involving collection procedures (Table 1). While
90% of URD PBSC donations occurred in a single day, and
no collection took more than two days, 30% of RD
required two days, and 2% and 1% took three and four
days, respectively, with collection for one donor taking
place over five days (P<0.001). Notably, more RD were
collected with lower volume procedures (<18L, 40% vs.
26%; P<0.001). A major difference in RD versusURD prac-
tice was noted in the increase in central venous line place-
ment in RD for both female and male donors (female RD
38%, female URD 17%, P<0.001; male RD 12%, male
URD 2%, P=0.001).  Of note, the differences were not
impacted by age, although obesity had an impact in
female donors, and number of collection procedures per-
formed impacted both male and female donors (Online
Supplementary Table S2).
Univariate analyses of bone marrow collection, pain
and donation-related symptoms
Figure 1A and B show rates of grades 1-4 skeletal pain and
collection-related symptoms in RD and URD before, peri-
donation, and one year after the BM collection procedure.
Online Supplementary Figure S1A-D detail locations of pain
and types of symptoms experienced. It is notable that 5-
10% of healthy URDs and 10-20% of RDs reported mild
pain or symptoms pre-donation. Almost all donors reported
some level of pain or symptoms during the procedure;
however, because grade 1 pain and symptoms rarely
require intervention, we focused our analyses on higher
grades. Univariate analyses showed RD to have higher rates
of grade 2-4 pain pre-donation (2.4% vs. 0.6%; P=0.043)
(Online Supplementary Table S3). Grade 2-4 pain levels at col-
lection were similar, but grades 3-4 pain were substantially
higher in RD (10%  vs. 0.6%; P<0.001). At one year, 10%
and 5% of RD versus URD reported grade 2-4 pain
(P=0.060). Pre-donation, MTC symptoms were similar in
RD and URD. At collection, grade 2-4 and 3-4 symptoms
were higher in RD versus URD (24% vs. 17% grade 2-4,
3.3%  vs.  0.4% grade 3-4; P=0.049 and 0.002, respectively),
with higher rates of dizziness, site reactions, nausea, and
syncope in RD (P=0.005, 0.008, 0.021, and 0.028, respec-
tively)  (Online Supplementary Figure S1C).
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Figure 1.  Severity of skeletal pain
and highest toxicity level across key
body symptoms experienced by first
time related versus unrelated bone
marrow donors at baseline, two days
post donation, and one year post
donation. (A) Skeletal pain. (B)
Highest toxicity level across key body
symptoms.
A
B
Univariate analyses of peripheral blood stem cell 
collection, pain and donation-related symptoms
Figure 2A and B show rates of grades 1-4 skeletal pain
and MTC symptoms in RD and URD before, on day +5 of
G-CSF administration (day of peak symptoms), and one
year after the PBSC collection procedure. Online
Supplementary Figure S2A-D detail locations of pain and
types of symptoms experienced by RD and URD undergo-
ing PBSC collection. Online Supplementary Table S4 shows
that at pre-donation baseline, day +5 of G-CSF, and one
year, all measures of grade 2-4 and 3-4 pain are higher in
RD compared to URD (all P<0.001). In addition, 10%
fewer RD return to pre-donation levels of pain at one year
(P<0.001). Collection-related MTC symptoms are also
experienced significantly more and to a higher degree at
all time points, and non-recovery to pre-donation levels of
these symptoms at one year occurs more often after RD
procedures (17% vs.  12%; P<0.001).  
Multivariate analyses of bone marrow and peripheral
blood donor experiences: related versus unrelated
donor
Multivariate analysis showed that Grade 2-4 pain after
BM collection was similar between RD and URD (Table
2). Grade 2-4 symptoms after BM collection were 1.5
times more likely for RD, but this did not reach signifi-
cance (P=0.075). Related PBSC donors were at higher risk
for grade 2-4 and 3-4 pain (OR 1.42, 8.91, respectively;
both P<0.001) and grade 2-4 symptoms (OR 1.84;
P<0.001) with collection, as well as the presence of grade
2-4 symptoms at one year (OR 1.56; P=0.021). A notable
finding was that RD reporting no comorbidities had a risk
of grade 2-4 pain at one year similar to URD. But if RD
reported any comorbidities, their risk of grade 2-4 pain
was significantly increased, with the highest risk noted in
RD with comorbidities that would have led to deferral by
NMDP standards (OR 3.43; P<0.001).
Table 2 also describes analyses of failure to recover to
pre-donation levels of pain and donation-related symp-
toms at one year. RD of PBSC had an OR of 1.42 for non-
recovery to pre-donation levels of pain at one year
(P=0.001). Recovery to pre-donation levels of symptoms
was associated with comorbidity: RD who had no comor-
bidities were similar to URD, but RD who had comorbidi-
ties had a higher risk of non-recovery at one year. Notably,
RD identified as having comorbidities that would have led
to NMDP deferral had a more than 3-fold increase in risk
of non-recovery to pre-donation levels compared to URD
(OR 3.71; P<0.001).  
Multivariate analysis: other factors affecting risk of
pain, symptoms, or non-recovery at one year
For BM donation, women were 67% more likely to
experience grade 2-4 pain and nearly 3 times more likely
to experience grade 2-4 symptoms (P<0.001) (Table 3).
Age was an important risk factor for failure to recover to
pre-donation levels, as donors aged 50-60 years were
more than twice as likely as their younger counterparts to
have non-recovery at one year (Table 4). In addition,
women’s risk of non-recovery at one year to pre-donation
levels of symptoms was twice that of men (P<0.001).
Risk factors for pain and MTC symptoms after PBSC
collection included both new and previously described
clinical characteristics (Tables 3 and 4). A new finding is
that high CD34+ counts (≥80.5/mL) prior to day 1 of collec-
tion was associated with more grade 2-4 collection pain
(OR 1.25; P<0.001). Another novel finding was that there
was a dose level of G-CSF above which pain levels
increased significantly. If a donor received an average daily
dose exceeding 960 mg/day, reported pain levels were
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Table 2. Multivariate analysis of collection toxicities and long-term recovery after bone marrow (BM) and peripheral blood stem cell (PBSC)
donations showing the effect of donor type. The odds ratios are for comparing related donor (RD) versus unrelated donor (URD).
                                                                                                            BM donors                                                PBSC donors
Event and time point                                                                           OR (95% CI)                      P                       OR (95% CI)                          P
Skeletal pain                                                                                                                                                                                                                                                 
Grade 2-4 at collection                                                                                   1.19 (0.81-1.74)                      0.375                       1.42 (1.17-1.72)                        <0.001
Grade 3-4 at collectiona                                                                                                                                                                    8.91 (6.63-12.0)                        <0.001
Grade 2-4 at one yeara                                                                                                                                                                                                                         <0.001
RD, comorbidities absent                                                                                                                                                            1.02 (0.63-1.65)                          0.944
RD, comorbidities present, acceptable                                                                                                                                    2.66 (1.60-4.42)                        <0.001
RD, comorbidities present, indeterminate                                                                                                                             1.62 (1.04-2.52)                          0.033
RD, comorbidities present, defer                                                                                                                                              3.43 (1.86-6.35)                        <0.001
Non-recovery to pre-donation level at one year                                      0.96 (0.56-1.63)                      0.871                       1.42 (1.15-1.74)                          0.001
Max MTC symptoms                                                                                                                                                                                                                                   
Grade 2-4 at collection                                                                                   1.50 (0.96-2.36)                      0.075                       1.84 (1.49-2.28)                        <0.001
Grade 2-4 at one yeara                                                                                                                                                                      1.56 (1.07-2.27)                          0.021
Non-recovery to pre-donation level at one year                                      1.08 (0.58-2.01)                      0.819                                                                            <0.001
RD, comorbidities absent                                                                                                                                                            0.94 (0.64-1.37)                          0.743
RD, comorbidities present, acceptable                                                                                                                                    1.98 (1.26-3.12)                          0.003
RD, comorbidities present, indeterminate                                                                                                                             1.77 (1.24-2.52)                          0.002
RD, comorbidities present, defer                                                                                                                                           3.71 (2.14-6.45)                        <0.001
OR: odds ratio; CI: Confidence Interval; Max: maximum; MTC: Modified Toxicity Criteria. aNumber of events for BM donors was not sufficient for multivariable analysis.
higher (OR 1.21; P=0.006). This increase in pain levels was
not noted when analyzed by dose per/kg.  
Females undergoing PBSC collection had twice the risk
of moderate and severe pain and MTC symptoms (Table
3). They were also more likely to have persistent symp-
toms and to fail to recover to pre-donation levels at one
year after BM collection (Table 4). The age effect varied,
with PBSC donors aged 30-39 years having higher risk for
grade 3-4 pain with collection (OR 1.50; P=0.021) (Table 3)
and older donors (aged 50-60 years) having lower risks for
grade 2-4 pain with collection (OR 0.61; P<0.00) (Table 3)
and higher risks of reporting grade 2-4 pain at one year
(aged 50-60 years: OR 2.72; P<0.001) (Table 4).
Importantly, donors who started with grade 1 or 2-4 pain
or grade 2-4 MTC symptoms were more likely to report
higher grades of pain or symptoms with collection
(P<0.001) (Table 3). These donors also had higher levels of
pain and MTC symptoms at one year, but most of them
had returned to pre-donation levels. Obesity was impor-
tant in pain and MTC symptom risk, as donors with 30+
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Table 3. Multivariate analysis showing other key predictors for skeletal pain and Modified Toxicity Criteria (MTC) symptoms associated with bone
marrow (BM) and peripheral blood stem cell (PBSC) collections.
                                                                             Grade 2-4 skeletal pain                  Grade 3-4 skeletal pain                         Grade 2-4 max MTC 
                                                                                     at collection                                   at collection                              symptoms at collection
Variable                                                       OR (95% CI)                        P                  OR (95% CI)               P             OR (95% CI)                  P
BM donation                                                                                                                                                                              
Gender                                                                                                                                                                                                                                                             
Male                                                                               1.00                                                                                                                                   1.00                                
Female                                                                1.67 (1.41-1.97)                      <0.001                                                                           2.74 (2.23-3.37)               <0.001
PBSC donation                                                                                                                                                                           
Gender                                                                                                                                                                                                                                                             
Male                                                                               1.00                                                                       1.00                                                     1.00                                
Female                                                                1.76 (1.60-1.93)                      <0.001               2.18 (1.69-2.81)           <0.001         1.91 (1.65-2.20)               <0.001
Age at collection (years)                                                                                    <0.001                                                        0.005                                                       0.013
18 to 29                                                                          1.00                                                                       1.00                                                     1.00                                
30 to 39                                                                1.00 (0.90-1.12)                        0.977                1.50 (1.06-2.12)             0.021           1.18 (0.98-1.41)                0.080
40 to 49                                                                0.85 (0.75-0.96)                        0.008                1.19 (0.83-1.72)             0.340           1.26 (1.05-1.53)                0.015
50 to 60                                                                0.61 (0.52-0.71)                      <0.001               0.77 (0.51-1.16)             0.216           0.91 (0.72-1.16)                0.452
Donor BMI                                                                                                              <0.001                                                      <0.001                                                    <0.001
Underweight / normal                                                1.00                                                                       1.00                                                     1.00                                
Overweight                                                        1.13 (1.02-1.26)                        0.021                1.30 (0.92-1.84)             0.137           1.31 (1.10-1.57)                0.003
Obese                                                                 1.35 (1.18-1.55)                      <0.001               2.03 (1.47-2.82)           <0.001         1.63 (1.36-1.96)               <0.001
Unknown                                                            0.92 (0.52-1.63)                        0.776                1.21 (0.48-3.05)             0.686           1.11 (0.50-2.45)                0.806
Number of days of collection                                                                                                                                                                                                                     
1 day                                                                               1.00                                                                                                                                                                          
2+ days                                                               0.74 (0.64-0.85)                      <0.001                                                                                                                             
G-CSF dose                                                                                                              0.007                                                                                                                              
0-960 g/day                                                                   1.00                                                                                                                                                                          
>960 g/day                                                         1.21 (1.06-1.38)                        0.006                                                                                                                              
Unknown                                                            1.37 (0.96-1.97)                        0.086                                                                                                                              
Skeletal pain pre-donation                                                                                 <0.001                                                        0.004                                                       0.006
Grade 0                                                                          1.00                                                                       1.00                                                     1.00                                
Grade 1                                                               1.57 (1.36-1.82)                      <0.001               1.39 (0.95-2.02)             0.087           1.31 (1.05-1.64)                0.016
Grade 2-4                                                            2.47 (1.77-3.46)                      <0.001               2.33 (1.37-3.96)             0.002           1.65 (1.08-2.52)                0.020
Max MTC pre-donation                                                                                                                                                            0.030                                                      <0.001
Grade 0                                                                                                                                                       1.00                                                     1.00                                
Grade 1                                                                                                                                             0.85 (0.54-1.34)             0.477           1.37 (1.06-1.77)                0.017
Grade 2-4                                                                                                                                         2.67 (1.22-5.82)             0.014           3.23 (1.86-5.61)               <0.001
Absolute CD34+ at pre-collection                                                                     <0.001                                                                                                                             
<80.5                                                                              1.00                                                                                                                                                                          
≥80.5                                                                    1.25 (1.14-1.37)                      <0.001                                                                                                                             
Unknown                                                            1.14 (0.87-1.48)                        0.341                                                                                                                          
OR: odds ratio; CI: Confidence Interval; BMI: Body Mass Index; G-CSF: granulocyte-colony stimulating factor; Max: maximum.  
BMI had increased risk of peri-collection grade 2-4 and 3-
4 pain and grade 2-4 MTC symptoms, along with grade 2-
4 pain at one year. 
Table 4 shows additional factors other than RD/URD
status associated with higher levels of late pain/MTC
symptoms and lack of recovery to pre-donation levels at
one year. Older BM and PBSC donors, and Black and mul-
tiple-race PBSC donors were less likely to recover to their
pre-donation level of pain. Hispanic and multiple-race
PBSC donors were less likely to recover to pre-donation
level of MTC symptoms. As might be expected, donors
with pre-donation levels of pain or symptoms at grade 1
or grades 2-4 were more likely to recover to that level at
one year. 
Discussion
Unrelated HSC registries have a responsibility to ensure
the safety of volunteer donors performing an altruistic
act.17 They routinely defer donors with minor health prob-
lems, erring on the side of safety. Transplant centers,
whose primary task is treatment of patients with cancer
and other life-threatening illnesses, must also evaluate the
medical fitness of donors and advise them about risk, in
some cases deferring them. Although recent changes in
accreditation requirements for transplant centers empha-
size donor education and autonomy, requiring an inde-
pendent donor advocate,18-20 RD may or may not listen to
advice to forgo donation, being highly motivated and will-
ing to take medical risks for their family member. 
Studies have shown that a matched sibling is generally
the best HSC donor;21-23 and recent expansion of hap-
loidentical approaches24 have put even more family mem-
bers into a donor role. Over the past decade, however,
improvements in URD procedures have led to comparable
outcomes using RD and URD in patients with hematolog-
ic malignancies,25-27 offering reasonable HCT alternatives if
a RD is unable to donate. With this in mind, when should
a transplant center counsel a RD against donation?
Our study shows that the choice to donate by a RD
with comorbidities can have consequences.  We show by
multivariate analysis that RD have more intense early pain
and toxicities than URD, and because these symptoms are
temporally associated with PBSC collection, there is little
doubt that the toxicities are related to the donation proce-
dure. There is a question, however, about whether our
observation that RD have more pain and non-recovery to
pre-donation levels at one year is due to the procedure
itself, or other aspects associated with being a RD.
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Figure 2.  Severity of skeletal pain and
highest toxicity level across key body
symptoms experienced by first time relat-
ed versus unrelated peripheral blood stem
cell (PBSC) donors at baseline, on the first
day of collection prior to apheresis, and
one year post donation. (A) Skeletal pain.
(B) Highest toxicity level across key body
symptoms.
A
B
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Table 4. Multivariate analysis showing other key predictors for long-term skeletal pain and Modified Toxicity Criteria (MTC) symptoms and recovery
to pre-donation level after bone marrow (BM) and peripheral blood stem cells (PBSC) donations.
                                                           Grade 2-4 skeletal                  Grade 2-4 max                   Skeletal pain                Max MTC symptoms
                                                                       pain                             MTC symptoms                   non-recovery                     non-recovery
                                                                     at one                                  at one                    to pre-donation level             to pre-donation 
                                                                      year                                     year                             at one year                    level at one year
Variable                                         OR (95% CI)              P            OR (95% CI)        P          OR (95% CI)          P              OR (95% CI)           P
BM donation                                                                                                                                                                                                                                      
Gender                                                                                                                                                                                                                                                            
Male                                                                                                                                                                                                                                1.00                       
Female                                                                                                                                                                                                                1.92 (1.35-2.74)       <0.001
Age at collection                                                                                                                                                                             0.012                                                     
18 to 29                                                                                                                                                                   1.00                                                                               
30 to 39                                                                                                                                                         1.13 (0.78-1.63)      0.521                                                     
40 to 49                                                                                                                                                         1.42 (0.95-2.12)      0.091                                                     
50 to 59                                                                                                                                                         2.21 (1.34-3.64)      0.002                                                     
Skeletal pain pre-donation                                                                                                                                                                                                                        
Grade 0                                                                                                                                                                   1.00                                                                               
Grade 1-4                                                                                                                                                     0.39 (0.20-0.74)      0.004                                                     
Max MTC symptoms pre-donation                                                                                                                                                                                                          
Grade 0                                                                                                                                                                                                                          1.00                       
Grade 1-4                                                                                                                                                                                                            0.29 (0.11-0.72)        0.008
PBSC donation                                                                                                                                                                                                                                   
Gender                                                                                                                                                                                                                                                            
Male                                                                                                                         1.00                                                                                                                               
Female                                                                                                         1.61 (1.15-2.25)    0.005                                                                                                       
Age at collection (years)                                                       <0.001                                                                                         <0.001                                                   
18 to 29                                                         1.00                                                                                                   1.00                                                                               
30 to 39                                               1.81 (1.19-2.74)           0.005                                                          1.50 (1.21-1.86)     <0.001                                                   
40 to 49                                               1.85 (1.22-2.82)           0.004                                                          1.78 (1.43-2.22)     <0.001                                                   
50 to 60                                               2.72 (1.77-4.16)          <0.001                                                        2.18 (1.71-2.78)     <0.001                                                   
Donor BMI                                                                                  0.013                                                                                                                                                          
Underweight / normal                               1.00                                                                                                                                                                                         
Overweight                                       1.36 (0.95-1.95)           0.097                                                                                                                                                          
Obese                                                1.79 (1.25-2.57)           0.002                                                                                                                                                          
Unknown                                           0.96 (0.31-2.94)           0.943                                                                                                                                                          
Donor race                                                                                <0.001                                                                                          0.001                                                0.015
Caucasian                                                     1.00                                                                                                   1.00                                                1.00                       
Hispanic                                             1.45 (0.90-2.33)           0.127                                                          1.14 (0.85-1.54)      0.377            1.54 (1.09-2.18)        0.014
African / African American            2.91 (1.74-4.84)          <0.001                                                        2.05 (1.40-3.00)     <0.001          1.42 (0.87-2.32)        0.166
Asian / Pacific Islander                   2.18 (1.26-3.77)           0.006                                                          1.22 (0.87-1.71)      0.243            1.25 (0.81-1.91)        0.310
Multiple races / other                    1.88 (1.09-3.22)           0.023                                                          1.52 (1.11-2.08)      0.009            1.62 (1.11-2.38)        0.013
Year of collection                                                                                                                                                                                                                                         
2010-2011                                                                                                                                                                                                                       1.00                       
2012-2013                                                                                                                                                                                                            0.74 (0.61-0.91)        0.004
Skeletal pain pre-donation                                                   <0.001                                        0.044                                       <0.001                                              0.004
Grade 0                                                         1.00                                                   1.00                                         1.00                                                1.00                       
Grade 1                                              3.17 (2.27-4.43)          <0.001        1.69 (1.04-2.72)    0.033       0.53 (0.40-0.71)     <0.001          1.67 (1.23-2.27)        0.001
Grade 2-4                                           3.09 (1.71-5.60)          <0.001        1.94 (0.86-4.34)    0.109       0.22 (0.11-0.45)     <0.001          1.35 (0.71-2.59)        0.362
Max MTC symptoms pre-donation                                       0.040                                          0.003                                                                                                 <0.001
Grade 0                                                         1.00                                                   1.00                                                                                                1.00                       
Grade 1                                              0.74 (0.46-1.20)           0.225          1.00 (0.55-1.82)    0.998                                                              0.27 (0.15-0.47)       <0.001
Grade 2-4                                           3.04 (1.10-8.42)           0.033         5.28 (2.04-13.60)   0.001                                                           0.17 (0.02-1.31)        0.089
OR: odds ratio; CI: Confidence Interval; BMI: Body Mass Index; Max: maximum.
Although attempting to link observed pain at one year
directly to PBSC donation was not one of our objectives,
an observation that we made may shed light on this ques-
tion.  We performed additional assessments of RD at one
and six months; we noted that the donation pain levels do
not fully recover at one month, and remain at heightened
levels at six and 12 months (P>0.001) (Online
Supplementary Figure S3), suggesting that persistently ele-
vated pain levels are a consequence of donation.  
Given that elevated post-donation pain levels were only
grade 1 or 2 (mild/moderate), are these findings clinically
significant? This is an important question because self-
reported pain from individuals can vary based on charac-
teristics such as gender or cultural differences. To define
whether the persistent pain we detected was clinically
meaningful, we performed an analysis of the relation of
reported pain to donor HR-QoL. In a companion study
imbedded in our protocol, 186 RD and URD were ran-
domly chosen for assessment of HR-QoL. We noted that
at one month and one year after donation, those reporting
grade 2 pain or toxicities had significantly lower physical
scores measured by the SF36 multidimensional HR-QoL
measure compared to those not reporting pain or toxici-
ties [P=0.002 (1 month) and 0.004 (1 year)] (Online
Supplementary Figure S4). The findings of our HR-QoL
companion study (reported separately) support the out-
comes we report (e.g. RD reported the donation to be
more painful than URD; at 1 year RD were less likely to
feel back to normal and reported a longer period of recov-
ery). These observations allow us to conclude that the per-
sistent pain is clinically meaningful, but the cause of high-
er levels of persistent pain in RD is unclear.  Future studies
could explore potential contributing factors, such as the
possibility of G-CSF increasing inflammation in donors
with comorbid conditions or the relationship of persistent
pain to psychological stressors experienced by family
donors.
With this in mind, should RD at highest risk of pain or
non-recovery consider deferral? Deferring RD who would
have been deferred by the NMDP (our highest risk group)
is in line with a recent Worldwide Network for Blood and
Marrow Transplantation task force recommendation to
screen RD using URD registry standards.9,28  It is likely that
unless transplant centers collecting RD accept limits on
screening and collection similar to URD registries, RD will
remain at higher risk for pain/toxicity and lack of recov-
ery. But should pre-donation standards for deferral of a
RD be similar to those for URD? Although there is no
clear medical benefit from donation, there is evidence that
both URD and RD may experience psychosocial benefits,
including feelings of enhanced self-worth. For RD, there
are additional benefits of alleviating the suffering or saving
the life of a loved one and closer family relationships.29-31
While some family members may willingly accept
increased medical risk in exchange for psychosocial bene-
fits, others may hesitate and feel coerced by family obliga-
tions. Striking a balance is a challenge, as transplant cen-
ters should support the wishes of RD who are ambivalent
about donation and protect those in whom donation
could be a serious risk. But at the same time, RD should
have the choice as to whether to shoulder some level of
increased risk.  
This study identified a series of risk factors that could
either motivate a transplant center to recommend against
use of a given donor, or allow a donor with multiple risk
factors to understand their risk and choose to forgo dona-
tion (Tables 3 and 4). A desired outcome from this study
is to motivate transplant centers to test interventions
aimed at minimizing discomfort or preventing persistent
pain or symptoms experienced by high-risk RD. The data
on risks presented herein should be shared with RD as
part of their counseling regarding the donation process. 
In summary, this study showed for the first time that
adult RD of PBSC are at increased risk for higher levels of
pain and symptoms in the short-term after a collection
procedure and one year later compared to URD. The pres-
ence of comorbidities in a prospective donor heightens
this risk, and comorbidities in combination with other fac-
tors described in this study should be carefully considered
as transplant teams and individuals make decisions
regarding BM or PBSC donation.
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